SGShannon Galvin

Shannon Galvin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shannon Galvin has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rapid Deployment of Telemedicine in HIV Care: Mixed Methods Study of Providers’ Attitudes and Perceptions

    by Shannon Galvin, Artur Queiroz, Juan Rivera, Mia Calamari, Katherine Wright, Lisa R Hirschhorn, Laura Rusie, Patrick Janulis, Rebecca Kumar, Frank Palella, et al.

    Background: The COVID-19 pandemic prompted an abrupt transition to telemedicine for HIV care, necessitating the exploration of provider attitudes and experiences to understand its ongoing viability and impact. Objective: This study aimed to assess providers’ attitudes toward and experiences with telemedicine at HIV clinics in the Chicago area during the COVID-19 pandemic at 2 time points and at 2 clinical sites. Methods: We conducted a convergent mixed methods study to evaluate and explore providers’ attitudes toward and experiences with telemedicine at HIV clinics in the Chicago area during the COVID-19 pandemic, applying the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) framework and the updated Consolidated Framework for Implementation Research. This study assessed HIV providers via surveys at 2 time points, capturing responses on the acceptability, appropriateness, feasibility, and maintenance of telemedicine. Semistructured key informant interviews were conducted on a random selection of 10 participants to explore perceived experiences with telemedicine. Results: Among emailed providers, 43 of 83 (51.8%) and 27 of 82 (32.9%) responded to survey 1 and survey 2, respectively. The first survey recorded telemedicine usage at 75%, which decreased to 58% by the second survey. Overall, the majority of respondents agreed with statements that assessed telemedicine as appropriate, acceptable, and feasible. There were overall few statistical differences in responses between sites, although more providers at the community site indicated at least some potential value in telemedicine when compared to providers at the university hospital (100% agree or strongly agree vs 82.3%; P =.04) in survey 1. In survey 1, providers with more than 10 years of experience were less likely to report telemedicine helped them see more patients (31.6% agree or strongly agree vs 70.6% for providers with ≤10 y of experience; P =.008). Fewer experienced providers felt they could talk about private issues with their patients during telemedicine (57.9% of more experienced vs 88.3% of less experienced providers; P =.03). Key informant interviews provided qualitative insights into telemedicine integration, revealing mixed sentiments; providers appreciated the flexibility and accessibility that telemedicine offered but preferred in-person visits for their thoroughness, especially for physical examinations and laboratory tests. Despite initial barriers such as technical challenges and patient preferences for in-person visits, telemedicine was deemed feasible for maintaining communication and care quality. Providers highlighted the need for better technological support and ongoing training to optimize telemedicine usage. Conclusions: Our study underscores telemedicine as a sustainable adjunct to traditional HIV care, emphasizing the importance of addressing technological and training barriers to enhance its efficacy.

  • Open Access

    Individualizing beta-lactam dosing in real-world patients: lessons from a pharmacist-led programme implementation and evaluation

    by Samantha Pan, Erin Weslander, Sarah Fierek, Mark Ball, Christopher A Crutchfield, Shannon Galvin, Nathaniel J Rhodes

    Individualized dosing of beta-lactam using serum concentrations is an emerging approach to overcome PK/PD variability in select patients. Herein, we describe a beta-lactam dose individualization programme highlighting successes and challenges. We conducted a single-centre evaluation of a beta-lactam dose individualization using serum concentration monitoring programme. In September 2023, a pharmacist-driven protocol was implemented at an academic centre as a collaboration between Infectious Diseases, Pharmacy, and the Clinical Laboratory. De-centralized pharmacists ordered serum concentrations for cefepime, meropenem or piperacillin-tazobactam treated patients. Interpretation was conducted using Bayesian software. The drug monitored, treatment indication, model fitness, whether therapy was altered, whether protocols were followed and PK/PD attainment for each patient were recorded. Eighty-two beta-lactam serum levels were ordered in 47 patients between 26 September 2023 and 31 March 2024. Cefepime was most frequently monitored (70.7%). Common treatment indications in monitored patients were hospital-acquired/ventilator-associated pneumonia (25.5%), surgical prophylaxis (12.8%), bone/joint (12.8%) and central nervous system infection (12.8%). Model fitness was good or intermediate in >95% of cases. Dose or agent optimization was possible in 60% of cases, and dose adjustments were made in 34% of cases. Protocol deviations were common (57.4%). Targets of 100% fT>1×MIC and fT>4×MIC were achieved in 91.5% and 61.7% of patients, respectively. Troughs exceeding protocol safety goals occurred >20% of the time. We found that dose optimization was possible in >50% of monitored patients necessitating dose adjustments >33% of the time. Protocol deviations reinforced areas for continued pharmacist and provider education to optimize the use of this targeted intervention.

  • Open Access

    HIV Providers’ Attitudes Towards Telemedicine (Preprint)

    by Shannon Galvin, Artur Queiroz, Juan Rivera, Mia Calamari, Katherine Wright, Lisa Hirschhorn, Laura Rusie, Patrick Janulis, Rebecca Kumar, Frank Palella, et al.

    BACKGROUND The COVID-19 pandemic prompted an abrupt transition to telemedicine for HIV care, necessitating an exploration of provider attitudes and experiences to understand future viability and impact. OBJECTIVE We conducted a convergent mixed methods study to evaluate and explore the attitudes towards and experiences of telemedicine among providers at HIV clinics in the Chicago area. METHODS This mixed-methods study assessed HIV providers with surveys at two time points and key informant interviews. Surveys were administered via REDCap, capturing responses from 83 eligible providers on the acceptability, appropriateness, feasibility, and maintenance of telemedicine. Semi-structured key informant interviews were conducted on random selection of 10 participants to explore perceived experiences with telemedicine. RESULTS The first survey recorded telemedicine usage at 75%, which decreased to 58% by the second survey. Overall, the majority of respondents agreed with statements that assessed telemedicine appropriate, acceptable and feasible. Key informant interviews provided qualitative insights into telemedicine integration, revealing mixed sentiments; providers appreciated the flexibility and accessibility telemedicine offered but preferred in-person visits for their thoroughness, especially for physical exams and lab tests. Despite initial barriers such as technical challenges and patient preferences for in-person visits, telemedicine was deemed feasible for maintaining communication and care quality. Providers highlighted the need for better technological support and ongoing training to optimize telemedicine usage. CONCLUSIONS Our study underscores telemedicine as a sustainable adjunct to traditional HIV care, emphasizing the importance of addressing technological and training barriers to enhance its efficacy. CLINICALTRIAL N/A

  • Intra-operative redosing of cefepime in massive blood loss: population vs individualized approaches

    by Krista Paplaczyk, Erin Weslander, Adrian Valadez, Chitaru Kurihara, Shannon R. Galvin, Kyle Leonida, Griffin Reed, Nathaniel J. Rhodes


  • Open Access

    The value of repeat patient testing for SARS-CoV-2: real-world experience during the first wave

    by Alex Zhu, Margaret Creagh, Chao Qi, Shannon Galvin, Maureen Bolon, Teresa Zembower

    Introduction. Reports of false-negative quantitative reverse transcription PCR (RT-qPCR) results from patients with high clinical suspension for coronavirus disease 2019 (COVID-19), suggested that a negative result produced by a nucleic acid amplification assays (NAAs) did not always exclude the possibility of COVID-19 infection. Repeat testing has been used by clinicians as a strategy in an to attempt to improve laboratory diagnosis of COVID-19 and overcome false-negative results in particular. Aim. To investigate whether repeat testing is helpful for overcoming false-negative results. Methods. We retrospectively reviewed our experience with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing, focusing on the yield of repeat patient testing for improving SARS-CoV-2 detection by NAA. Results. We found that the yield from using repeat testing to identify false-negative patients was low. When the first test produced a negative result, only 6 % of patients tested positive by the second test. The yield decreased to 1.7 and then 0 % after the third and fourth tests, respectively. When comparing the results produced by three assays, the Centers for Disease Control and Prevention (CDC) SARS CoV-2 RT-qPCR panel, Xpert Xpress CoV-2 and ID NOW COVID-19, the ID NOW assay was associated with the highest number of patients who tested negative initially but positive on repeat testing. The CDC SARS CoV-2 RT-qPCR panel produced the highest number of indeterminate results. Repeat testing resolved more than 90 % of indeterminate/invalid results. Conclusions. The yield from using repeat testing to identify false-negative patients was low. Repeat testing was best used for resolving indeterminate/invalid results.